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Abstract

Introduction

Many methods have been used to study calcium
oxalate crystallisation. Most can be characterised by
changes in supersaturation during the experiment, which
may increase, remain constant or decay. Their ability to
quantify various aspects of crystallisation often reflects
the extent to which nucleation, growth and aggregation
can be measured independently, when two or three of
these processes may be occurring simultaneously.
The mixed suspension , mixed product removal
technique reaches a steady state supersaturation, is a
good model for intrarenal crystallisation and allows both
growth and nucleation rates to be measured. Using 92%
urine and comparing control urines with samples from
recurrent stone formers no difference in growth rates
was found but the controls had higher nucleation rates
(p=0.003) and lower supersaturations (p=0.001). In
parallel crystallisers running simultaneously , heparin or
hyaluronic acid addition to 92% urine was studied.
Both macromolecules increased growth rates, decreased
nucleation rates and increased supersaturation (p<0.05).
The steady state supersaturation achieved in this
system may be an important determinant of stone
forming potential. The ability to reach a lower urinary
supersaturation by increased nucleation may be a crucial
protective factor distinguishing non stone formers from
stone formers.

Many different methods have been used to study
calcium oxalate crystallisation, some differing in
technical detail and others at a more fundamental level.
Alternative approaches enable different types of
measurements to be made which may be most
appropriate for particular applications to urolithiasis
research; on the other hand, lack of standardisation of
methods used may be at least partly responsible for
contradictory results reported from apparently similar
experiments (Ryall et al., 1986a).
In order to appreciate the potential of different
methods , it is important to remember the underlying
processes involved in stone formation . These essentials
have been well described (Finlayson, 1978; Ryall, 1989)
as crystal nucleation, crystal growth (by precipitation of
fresh crystalline material from the surrounding liquor)
and crystal aggregation. Inhibition or promotion of any
of these processes in urine will reduce or enhance the
likelihood of stone formation and have therefore become
the focus of many in vitro urolithiasis studies (Fleisch,
1978).
Supersaturation is a prerequisite for
crystallisation. Two states of supersaturation have been
identified, a metastable state where crystallisation does
not occur unless perturbed by the addition of seed
crystals and an unstable state where crystallisation
occurs spontaneously . A metastable solution of calcium
oxalate can be forced into an unstable state by the
addition of more calcium or oxalate in the form of
dissolved salts.
This paper will review the more commonly used in
vitro techniques, discuss the principles by which they
operate, their strengths and weaknesses and identify
their role in the study of calcium oxalate crystallisation
and stone formation. It will also include some new
results obtained with a continuous flow method ,
modified to be applicable to nearly whole urine .

KEY WORDS :
Calcium oxalate, crystallisation,
urolithiasi s, crystal nucleation, crystal growth.
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Review of Methods

Supersaturation Decay Systems

Background Comments
Methods
for
studying
calcium
oxalate
crystallisation can broadly be divided into three main
types, depending on how the supersaturation changes
during the course of the experiment (Fig. 1). Firstly ,
the supersaturation may be allowed to decay; here
crystallisation is induced and allowed to proceed without
any further additions and the supersaturation of the
solution decreases as calcium oxalate crystallises.
Secondly, the supersaturation may be increased. In this
approach, initially stable solutions are concentrated to
induce crystallisation, with the aim of reproducing the
way the kidney brings about supersaturation. In the
third approach, constant supersaturation is maintained.
Calcium and oxalate are continuously added, again with
the intention of generating a better model of intrarenal
crystallisation than supersaturation decay systems.
Each of these three distinct approaches can be
applied in many different ways with different aims.
Crystallisation may be allowed to occur from simple salt
solutions, complex mixtures which mimic urine or urine
itself. When urine is included it may be very dilute ,
undiluted or concentrated.
The objectives of these
experiments are to better understand the physicochemical processes, to study the effects of certain well
defined chemical components and to investigat e the
influence of urine deriv ed macromolecules and/or to
compare urines from differ ent patients. A possible
application which has not been widely used is to
examine the value of potential therapeutic agents in vitro
with the urine of individual stone forming patients in
order to identify those most likely to benefit from a
particular treatment regime. This could be particularly
fruitful bearing in mind that any prophylactic regime
may have to be pursued for many years. After all, the
purpose of these experimental studies is to prevent stone
disease.
A variety of parameters may be measured by
different techniques , for example, the metastable limit
(onset of nucleation), nucleation rate, growth of crystal
mass as a whole or distinct from nucleation , growth of
crystal size which may include aggregation effects,
kinetic rate constants , inhibitor/promoter activities and
Langmuir adsorption isotherms. Apparently similar
parameters measured by different methods may yield
different results and have quite distinct meanings . On
the other hand, different groups have used different
nomenclature and formulations to express equivalent or
similar parameters .

Seeded Crystalliser Systems (Fig. 11 curve a)
General comments. One of the most common
approaches
to the study of calcium oxalate
crystallisation uses a metastable supersaturated solution
of calcium oxalate in which crystallisation is initiated by
the introduction of calcium oxalate monohydrate seed
crystals. The crystallisation process can be monitored .
by observing the size and number distribution of the
particles in suspension (Robertson & Peacock, 1972;
Robertson et al., 1973) or by following either calcium
(Meyer & Smith, 1975a) or oxalate (Ito & Coe, 1977;
Ligabue et al., 1979) depletion from solution or calcium
or oxalate incorporation into the solid phase (Will et
al., 1983).
Radioactiv e calcium or oxalate or
conventional chemical analysis may be used or the
reaction can be followed by conduc~vity (Nancollas &
Gardner, 1974), calcium ion electrode (Baumann et al.,
1990) or absorbance due to oxalate at 214nm
(Nakagawa et al., 1987).
In such seeded crystalliser systems, nucleation
should not occur, while both crystal growth and
aggregation may be taking place simultaneously. When
the particle size and number distribution is monitored
then both crystal growth (precipitation of fresh solid
phase) and aggregation will be reflected in the results,
but when calcium or oxalate removal from the solution
or incorporation into the solid phase is followed, only
crysta l growth is usually considered.
A frequent aim of crystallisation studies is to
quantify the ability of urine or particular components to
inhibit some aspect of the crystallisation process. This
is often achieved by comparing results under test
conditions (R_test) with a control experiment (R_ctl) and
defining the % inhibition as
I% = (l-(R_testlR-ctl)) x lOO
(l)
or
I% = ((R_cu-R-test)IR_ctl) x JOO
(2 )
It should be noted that equations 1 and 2 are equivalent.
Growth and aggregation considered as a combined
process.
When particle size analysis of seeded
crystalliser systems was first applied in the context of
kidney stone research , no attempt to distinguish growth
and aggregation processes was made. Instead these
were considered as combined effects by measuring the
increase in volume of only those particles greater than
20µm, 4 hours after seeding. Solutions containing test
inhibitors (Robertson et al., 1973), 5% urine (Robertson
& Peacock, 1972) or 1% urine (Robertson et al. , 1976)
were then compared against a saline control, allowing
the degree of inhibition , 1%, to be calculated.
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Figure 1. Diagrammatic representation of supersaturatio n changes that could occur in different methods for
studying calcium oxalate crystallisation; a, seeded, metastable system with supersaturation decay; b,
supersaturation raised above the metastable limit and allowed to decay; c, supersaturation increased by
evaporation; d, supersaturation increased by reverse osmosis; e, supersaturation increased by diffusion (e1,
unseeded , e2 , seeded); f, constant composition system; g, mixed suspension, mixed product removal method .
The grey scale represents the ill defined boundary between metastable and unstable supersaturation.
Growth and aggregation considered as separate and
independent processes. Ryall et al. (1981a) showed that
a given value of I% could result from very different
combinations of growth inhibition and aggregation
inhibition. This was achieved by considering growth and
aggregation to be independent of each other and treating
volume changes as being due to growth and changes in
particle numbers as a result of aggregation. They
applied this approach to dilute urine (2 to 10%) (Ryall
et al., 1981b) and to 1% urine and various inhibitors
(Ryall et al., 1981c). They found that the time (t)
course of volume changes (~ V) and particle number
changes (~
were non-linear, which led them to
criticise the use of an arbitrary fixed time for comparing
control and test experiments (Ryall et al., 1981b and
1981c). They overcame this problem by plotting t/~V
against t and t/LiN against t, which gave straight line

plots, from which the initial rates (~ V/4=0 and LiN/1t=o)
were found from the reciprocals of the intercepts on the
y axes at t=O. Inhibition of growth (lg%) and
aggregation (Ia%) were then calculated by comparing
test and control data.
This approach was elaborated upon, to take into
account particles growing or aggregating into or out of
the size range measured by the particle analyser (Ryall,
RG et al. , 1986) and has been applied to experiments
including 1% urine or inhibitors (Ryall, RL et al.,
1986b).
Growth considered as an independent process.
Some workers have considered growth and aggregation
in seeded systems to be independent of each other and
have therefore studied crystal growth kinetics simply by
following calcium or oxalate changes. In crystal seeded
metastable systems, calcium oxalate crystallisation is
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are empirical and will reflect particular experimental
conditions such as temperature (usually 37C), ionic
strength and the quality and surface area of the seed
crystals. If a tested inhibitor significantly associates
with calcium or oxalate, then this should be taken into
account by using activities rather than concentrations in
equation 4 (Meyer & Smith, 1975b) .
The % inhibition obtained from equations 5 or 6
can be used to make comparisons of different inhibitors
at the particular concentrations tested, or to infer the
relative amounts of inhibitor under particular
circumstances. This can be useful in following inhibitor
activity through a purification procedure (e.g. Ito & Coe,
1977; Nakagawa et al., 1981), examining the effect of
some treatment of an inhibitor (e.g. Fellstrom et al.,
1982) or comparing urines at a fixed dilution (e.g. 2%,
Ligabue et al., 1979). When comparing different
inhibitors and trying to gauge their likely significance in
vivo, it is important to consider the extent of inhibition
over a range of concentrations. The use of Langmuir
adsorption isotherms can be helpful in this respect,
particularly as this can give some insight into the
mechanism of inhibition.
Langmuir adsorption isotherms will apply if growth
inhibition is achieved when the inhibitor blocks growth
sites by binding to the seed crystals and adsorption of
further inhibitor is dependent only on the number of free
sites available, in which case simple saturation kinetics
will be obeyed ,
0 = k[I]/( 1+k[n)
(8)
where 0 is the proportion of sites occupied, k is an
adsorption coefficient and [I] is the inhibitor
concentration. If the crystal growth rate is proportional
to the number of free sites (1-0) then
[I] = CKcffKtest)fkKctl + 1
(9 )
or
[I] = (Kcti-Ktest)fkKrest
(lO)
and a plot of Kct1f<Kcti-Ktest) against 1/[I] (e.g. Meyer
& Smith, 1975b ; Nakagawa et al., 1981)) , KresJCKctl Ktest) against 1/[I] (e.g. Nakagawa et al., 1985) or
Ln((Kctl - Krest)IK 1est) against Ln[I] (Kok et al., 1986a)
will be a straight line with k obtained from the slope
(first two plots) or intercept (log plot). A good fit of
experimental data to such a line supports the mechanism
of inhibition of blocking growth sites by reversible
binding and k is an indication of the potency of the
inhibitor, being the concentration required to halve the
growth rate in the absence of inhibitor. Meyer & Smith
(1975b) proposed this method for comparing the
inhibition due to different components and for
quantifying the inhibition of different urine samples.
This would require measuring rate constants (Ktest) for

usually found to follow second order reaction kinetics
with the rate of reaction being proportional to the square
of the driving force for crystallisation (relative
supersaturation, RS),
2
-dRS/dt = K(RS-1)
(3)
where K is a rate constant (Finlayson, 1978; Curreri et
al ., 1981).
Generally , when working within restricted ranges
of conditions, it has been possible to simplify equation
(3) to calcium activities (Nancollas & Gardner, 1974;
Meyer & Smith 1975a), calcium concentrations (Ito &
Coe, 1977) or oxalate concentrations (Ligabue et al.,
1979), for example,
2
-dM/dt = K([Mtl-[Mt=eqD
(4)
where [Mtl and [Mt=eql are the solution concentrations
or activities of calcium or oxalate at time t and at
equilibrium, respectively.
This description of the crystal growth kinetics
allows quantitative comparisons of related experiments
to be expressed in various ways. A simple approach is
to measure the decrease in calcium or oxalate between
the initial time and some fixed time (~[Mlt). (For
example, t=40 minutes , Ito & Coe, 1977; t=2.5 hours ,
Ligabue et al., 1979; t=4 hours, Koide et al ., 1981; t=I
hour , Fellstrom et al., 1982). The % inhibition can then
be calculated as,
I% = (l-(MM]t testl~[M]t cti)) x lOO
(5)
or when a rate constant (K) is calculated, as,
I%= (1-(K_testlK-ctl)) x 100
(6)
In order to calculate the rate constant K (in
equation 4) , some estimate of [½=eql can be made and
calcium or oxalate measured at time intervals . K can
then be conveniently obtained from the slope of the
straight line plot of 1/([Mt]-[Mt=e<J]) against t. Meyer
& Smith (1975a) and Ito & Coe (1977) measured the
solubility product under their experimental conditions by
allowing dissolution or crystal growth experiments to
reach equilibrium and used the average of these values
to calculate [½=eql · The amount of calcium or oxalate
at a fixed time has been taken to approximate to the
equilibrium position. (For example, 4 weeks , Gill et al.,
1977; 24 hours, Ligabue et al., 1979; 3 hours , Fellstrom
et al., 1982).
An alternative is to use nonlinear
regression to the [M] versus t data to give estimates of
Kand [½=egl (Nakagawa et al., 1981, 1985). Rather
than collect data at many time points, a single time and
the equilibrium value can be used to obtain a simplified
estimate of K, as,
K = ~[Mtl/[½=eql
(7)
as before, different methods of estimating [Mt=e ] are
possible (Gill et al., 1977; Tiselius & Fornander, itJ81) .
However they are calculated, these rate constants
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a variety of dilutions of urine and has been applied to
urine with and without various inhibitors (Wemess et
al., 1981)
When urine has been studied in seeded
crystallisers, it has usually been diluted to between 1%
and 10%. This is because of the high inhibitory power
of urines in these systems and the requirement to have
the initial supersaturation close to control values, which
is not simply a matter of matching initial calcium and
oxalate concentrations . Baumann et al. (1990) have
tried to overcome these problems in a study using whole
urine .
In order to promote sufficient and rapid
crystallisation, they seeded their system with a high seed
concentration and followed the reaction with a calcium
ion electrode . They evaluated their results as h, the
time taken to reduce the calcium ion activity to half the
decrease over 20 minutes, by which time the reactions
appeared to be complete. The inhibitory effect of urine
or inhibitors was calculated as the increase in h
compared to a control experiment (htest-'hcu), which
appeared not to be strongly dependent on the urinary
concentration of calcium or oxalate.
Growth and aggregation considered separately but
not independently. The studies described above (and
many others) have taken the changes in calcium or
oxalate during the course of the experiment to be
representative of crystal growth only . This assumption
has been questioned (Blomen et al., 1983) . In a
thorough series of experiments Will et al. (1983) ,
Blomen et al. (1983) and Bijvoet et al. (1983) have
developed a general equation for calcium oxalate growth
in a metastable solution , se1fd with calcium oxalate
crystals.
In their system
Ca is included in the
metastable solution and its incorporation into the solid
phase is quantified at intervals and represented by the
fractional uptake (Ut) at time t,
O t = ([Mt=oJ-fMtD/[Mt=oJ
C11)
where [~=o] is the initial calcium concentration .
Second order kinetics were observed as previously,
expressed as,
dU/dt = UJlm((U 00 -Ul)/U 00
(12)
where U 00 is the maximum fractional uptake of calcium
that would occur for a particular experiment. The time
taken for the uptake to reach 50% of this value is lm·
(This therefore corresponds to the half time, h used by
Baumann et al ., 1990). U 00 can be obtained as the
reciprocal of the slope of the straight line plot of t/Ut
versus t, while lm is found from the intercept on the
t/Ut axis (lm/U 00 ) (Will et al., 1983). If U 00 is
comparable to [~=eq1 in the same way as U 1 and [M1]

equation 4 and UJlm is an empirical rate constant
related to K. In the following two papers of this series
(Blomen et al., 1983 & Bijvoet et al. , 1983), the
relationships between UJlm and the crystal seed
concentration , the initial supersaturation, ionic strength
and calcium to oxalate ratio were explored. This led to
the formulation of a comprehensive explanation of the
growth rate,
dU/dt = kAs[U
x
2
2
([C3t=o]/[C3t=eq1+[Ox 1=ol/[ Oxt=eqD ((U 00 -Ut)/U 00 )
(13)
where s is the crystal seed concentration, kA is the
crystal growth constant and [U00 ] is maximum fractional
uptake predicted from the initial and equilibrium
concentrations of calcium and oxalate . Considering
equations 12 and 13, the empirical rate constant for a
particular set of experimental conditions is explained,
UJlm = kAs[U 00 ] x
00 ]

2

([C3t=o)/[C3t=eql+[Oxt=O]/[Oxt=eqD
(14)
and rearranging this kA is found from equation 15 (Kok
et al., 1988).
1/kA = ([Uoo]Slm/Uoo)x
2
( [C3t=o]/[ Cat=eq1+ [Oxt=o]/[ Oxt=eq])
( 15)
The equilibrium concentrations ([C3t=eqL[Ox 1=eqD
are found from a series of separate experiments w~ch
4
identify the minimum concentration at which
Ca
uptake will occur (Blomen et al. , 1983) and can be used
to calculate [U00 ]. U00 and lm are obtained from the
growth curve as described above (Will et al. , 1983).
Once k A is found for test and control conditions the %
growth inhibition is readily calculated.
The crucial difference between the approach of this
group and previous studies is the distinction they draw
between [U00 ] and U 00 • The difference between [U00 ]
and U 00 was most pronounced at low seed
concentrations and has been attributed to aggregation
(Blomen et al ., 1983). They were able to quantify this
effect by the parameter [lm], the time when uptake
reaches 50% of [U00 ];
[lm] = lm([Uoo]/([U00 J-U00 ))
(16)
which increases with inhibition of aggregation .
The suggested mechanism for the influence of
aggregation on the initial supersaturation and hence on
the growth kinetics by reducing U 00 was that the
solution included within aggregates might not be
representative of the bulk solution and some of the
crystal growth surfaces would be exposed to lower
supersaturations than expected from the calcium and
oxalate concentrations (Kok et al., 1988).
Some
justification for using [lml to describe the aggregation
during the progress of a crystal growth experiment
comes from analysis of particle size distributions in the

l

are related by equation 14, then the term ((U 00 -Ut)/U 00
in equation

12 is proportional to ([~]-[Mt=eqD

2

)2
in
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same system (Kok et al., 1988). Further support can be
seen by comparing Langmuir plots where k A is used or
when I% (as in equation 5) is calculated using the
fractional calcium uptake at a fixed time (20min).
Using k A gives a linear plot over a wider range of
inhibitor concentrations than does I% (Kok et al.,
1986a).
Crystal growth and aggregation have been
measured using this method to study the effect of
inhibitors (Kok et al., 1988), of urine (20%) (Kok et al.,
1986b, 1990a) and effects of dietary changes on urine
(Kok et al., 1990b). Some difficulties in interpretation
can arise if a compound is an inhibitor of both processes
(for example, citrate) because they are not independent.
A problem with 11mlas an indicator of aggregation is
that the increase associated with inhibition of
aggregation is not linear and 11mlwould tend to become
infinite at 100% inhibition of aggregation. Nevertheless,
11ml adds an extra dimension to the study of calcium
oxalate crystallisation in seeded systems.
It is not yet clear how the interpretation of
experiments might be affected where the effect of
aggregation on crystal growth kinetics was not taken
into consideration. Inhibition of aggregation might
diminish the apparent growth inhibition estimated by
these methods, with any effects expected to be more
pronounced at low seed concentrations. The means of
determining [Mi=eql can now be seen to be critical. In
some cases [Mi=egJ appears to correspond to [U
in
others to U and in others to an average of both. The
effect of lack of independence between growth and
aggregation may need to be examined on particle size
distribution data, where the analysis assumed they were
independent.
Concluding comments on seeded, supersaturation
decay systems. Crystallisation with supersaturation
decay , induced by crystal seeding, has been one of the
most widely used techniques for studying calcium
oxalate monohydrate crystallisation in vitro. It is
usually performed in simple buffered saline and the
accuracy and reproducibility that can be achieved make
it very useful in investigating the interactions between
possible inhibitors and the crystallisation processes of
growth and aggregation, in the absence of nucleation.
The ability to fit crystallisation data from these
experiments to simple equations gives confidence that
the extrapolated rate constants and percentage inhibition
values relate directly to some well defined physicochemical process . To take full advantage of this care
must be taken to be clear how rate constants and
equilibrium values have been calculated or estimated.
The relevance of measurements made in saline or
00

dilute urine to urinary stone formation has been
questioned by many authors (Fleisch, 1978; Robertson
et al. 1981; Ryall et al., 1986a). As methods have
evolved, comparisons with previous studies becomes
more difficult. It is unfortunate that similar terminology
has sometimes been used to cover different
measurements, while different but equivalent expressions
of the same formulae may give rise to further confusion.

Non Seeded Crystalliser Systems (Fig. 11 curve b)
General comments. Crystallisation can be induced
in simple salt solutions or urine by increasing the initial
supersaturation usually by the addition of oxalate in
solution. In these systems , nucleation, crystal growth
and aggregation may all occur simultaneously as the
supersaturation declines to an equilibrium value. The
progress of the crystallisation can be followed, as
before, by various means, such as measurement of
calcium by specific ion electrode, calcium or oxalate
determinations chemically or with radioactive tracers
(Gill et al., 1977; Rose, 1975; Garti et al., 1980; Koide
et al., 1981; Sarig et al., 1982), particle counting and
sizing (Robertson et al., 1981; Ryal! et al., 1985;
Tiselius , 1985), microscopic evaluation of crystals
(Grases et al., 1988), nephelometry (Sutor et al., 1979;
Grases et al., 1988) or visual estimation of turbidity
(Kohri et al., 1991).
The main problem with these methods is that
interpretation of the measurement s is more difficult than
with seeded systems. This is because aggregation and
growth will be dependent on the crystal surface area
(which will increase as a result of nucleation and growth
and decrease due to aggregation) and all three processes
will depend, to differing degrees , on the declining
supersaturation. In practice it is not possible to
distinguish rigorously between these different aspects of
crystallisation and attempts are not usually made to
measure physico-chemically meaningful rate constants.
As a consequence, the choice of experimental conditions
is often arbitrary and direct comparisons between
different methods can not necessarily be expected to be
valid.
At the supersaturations usually found in urine,
precipitation of calcium oxalate on surfaces and particles
unavoidably present in the crystalliser (heterogeneous
nucleation) is likely to predominate over direct
formation of calcium oxalate nuclei (homogeneous
nucleation) (Finlayson, 1978). When whole urine is
used, even if filtered, a highly variable concentration of
heterogeneous nucleators are likely to be introduced.
Metastable limits and nucleation tendency . The
supersaturation at which spontaneous nucleation and

],

00
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growth occur may be found by increasing the
concentration of oxalate (Pak & Holt, 1976; Ryall et al.,
1985; Tiselius, 1985) or oxalate and calcium (Gill et al.,
1977; Kohri , 1991). This supersaturation is usually
referred to as the metastable limit or as a formation
product. This concept does not have a strong theoretical
foundation (Finlayson, 1978) because it can not be
equated to an exact calcium and oxalate activity product.
Any estimate will depend on the method used to detect
significant crystallisation and the induction time allowed
for this precipitation to begin.
The initial burst of crystallisation will produce
particles too small for detection directly, or for
separation and quantification by chemical means .
Detection of the onset of crystallisation is thus limited
by the sensitivity of the method and will only be
triggered when crystals have also grown (and possibly
aggregated) sufficiently large to be measured .
Therefore, a rapidly growing/aggregating suspension
with a low nucleation rate may give a similar metastable
limit to a rapidly nucleating, slowly growing/aggregating
mixture.
The general approach to measuring a meta<;table
limit is to set up aliquots with increasing supersaturation
and determine the minimum value at which
crystallisation is observed at a fixed time (for example,
3 hours - Pak & Holt (1976); 30 minute s - Ryal! et al.
(1985); 5 minutes - Kohri et al. (1991) and various
times from hour s to days - Pak et al. (1975) and Gill et
al. (1977). It is to be expected that the measured
metastable limit would decrease if the observation time
is increased (as shown by Pale et al. (1975) and Gill et
al. (1977)).
Tiselius (1985) has used a slightly more complex
method of carefully timed addition of oxalate ,
observation (2 minutes later) and repeating the cycle
with further additions of oxalate (5 minutes after the
previous addition). This method was applied to filtered
urine , diluted to a fixed creatinine concentration (5mM),
or to 80% of its original concentration and the calcium
oxalate crystallisation risk (CaOx-CR) was defined as
the reciprocal of the oxalate concentration required to
bring about an initial burst of crystallisation. Baumann
(1988) has described a similar method to identify the
minimum oxalate concentration required to induce
precipitation; an oxalate solution is continually infused
into a calcium solution or urine, with the crystallisation
followed by nephelometry. Another variation, which
takes into account the endogenous urinary calcium by
comparison with an artificial urine standard curve, is the
oxalate tolerance test (Briellmann et al., 1985; Hering,
1988).

The amount of calcium or oxalate that must be
added to reach the metastable limit should depend on
the initial supersaturation as well as other factors. It
would be expected to decrease with increasing initial
supersaturations which is supported by the results of
Tiselius (1985) and Ryal! et al. (1985 and 1986a). Pak
& Holt (1976) take this into account by relating their
measured formation product to an empirically
determined activity product ratio (an estimate of
supersaturation) and call this the Formation Product
Ratio (FPR). Ryal! et al. (1986a) expressed their
results as both the rise in oxalate required to bring about
crystallisation and the product of the concentrations of
calcium and total oxalate (i.e. endogenous oxalate plus
that added).
Measurements of metastable limits as an indicator
of nucleation have been used to examine the effects of
various additions to simple salt solutions (Pale et al.,
1979), artificial urine (Gill et al., 1977), or whole urine
(Ryall et al., 1991). Urines from different patients (Pak
& Holt, 1976; Pale & Galosy , 1980; Ryall et al., 1985,
1986a; Tiselius, 1985) have been compared and
modification of whole urine by ultrafiltration (Edyvane
et al., 1987) or urate removal (Grover et al., 1990a) or
urate addition (Grover et al., 1990b) have been studied.
Although these methods for studying nucleation
tendency are not solely dependent upon nucleation they
have the great advantage of being able to be applied
simply to whole urine . Without taking into account the
initial supersaturation, direct comparisons between
samples may not be appropriate and practical variations
in the applications of the methods are likely to exert
considerable influence.
Crystallisation from above the metastable limit.
The effect of inducing crystallisation by rapidly raising
the supersaturation and then allowing it to decay may be
evaluated by following the time course of events or by
taking measurements at some arbitrary fixed time or
when crystallisation is almost complete. The difficulty
in interpreting these results in terms of the different
aspects of crystallisation has meant that the conclusions
often drawn are only general. For instance, Garti et al.
(1980) compared the time course of calcium activity
decay in artificial urine by adding inhibitors and
concluded that retardation of crystallisation by these
inhibitors is not identical with inhibition of
crystallisation, as the same end point could be reached.
The extent of crystallisation at a particular time
after initiation of nucleation can be used to give an
indication of the crystallisation potential of artificial
urine or dilute urine (Rose , 1975; Sutor et al., 1979)
and the inhibitory activity characterised by comparison
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with control experiments. Sarig et al. (1982) defined a
discrimination index (DJ .) as the log of the ratio of
calcium activity at two different times (0.5 minutes and
10 minutes),
DJ.= Ln([~=o .51/[Mt=lO])
(17)
They used this to compare urines diluted to 10% of their
initial concentration and to study the effect of urinary
ultrafiltration (Azoury et al., 1985). The discrimination
index was felt to reflect the inhibitory potential of
different samples.
Rather than use a single time or pair of time
points, Grases et al. (1988) used the initial rate of
increase in turbidity in 89% urine as a measure of
crystallisation and Bek-Jensen & Tiselius (1991) used an
empirical integral of the decay in oxalate in solution
over 30 minutes.
In a method designed to focus upon aggregation,
Koide et al. (1981) allowed the crystallisation to
continue for a much longer time (24 hours) after which
they determined the proportion of the total oxalate
precipitated (M_ppt) that was found in particles greater
than about 20µm and used this to calculate a non
aggregated ratio (NAR),
NAR = M_ppt(>20µm)/M_ppt
(18)
Ryall et al. (1985) have tried to obtain a better
insight into the time course and nature of the non
seeded crystallisation in urine by measuring particle
size distributions. In this method whole urine is used
and the amount of oxalate added to induce
crystallisation was 0.3 mM above the previously
determined metastable limit. They used the slope of the
linear portion of the volume data as a measure of crystal
growth rate. This is analogous to the treatment of
particle size distribution data from seeded crystalliser
experiments (Ryal! et al., 1981c), but growth rates from
the two systems should not be confused as the non
seeded system includes nucleation effects. The changes
in particle numbers can not similarly be ascribed simply
to aggregation, as had been done before, again because
of nucleation.
In a subsequent report Ryall et al. 1986a suggested
that the total crystal volume after 90 minutes is another
indicator of crystal growth and the peak size of the
particle distributions gives an indication of the extent of
aggregation. This method has been applied in a number
of studies with whole urine (Edyvane et al., 1987;
Grover et al., 1990a, 1990b; Ryall et al., 1991) and, in
combination with the determination of a metastable
limit, it has been possible to draw general conclusions
about the effect of an experimental treatment on
nucleation, growth and aggregation.
In a non seeded crystallisation experiment the

choice of conditions is likely to have a significant effect
on the outcome. The nucleation and growth rates will
depend on the supersaturation chosen to initiate
crystallisation which may in tum indirectly influence the
degree of aggregation that occurs. During the initial
period, nucleation will dominate over growth and
aggregation and this balance will continue to vary as the
supersaturation decreases , with aggregation possibly
being the predominant
process as equilibrium
approaches. If the aim of an investigation is to study
the effect of components in a well defined medium, non
seeded crystallisation experiments have little to offer in
comparison with seeded systems. The exception is
when a study of nucleation effects is planned.
In
experiments aimed at the study of whole urine, the
approach of Ryal! et al. (I 985) with a consistent choice
of starting supersaturation has much promise .
Increasing Supersaturation Systems

General comments. This group of techniques is
distinguished from those already described because the
method for increasing the driving
force for
crystallisation continues to be applied while precipitation
is taking place . Of course, when crystals start to form
this will tend to reduce the supersaturation and the
actual supersaturation during an experiment is unlikely
to be well defined.
It could be argued that some of the methods
already discussed above should belong in this section as
they used intermittent (Tiselius, 1985) or continuous
addition of oxalate solution (Baumann, 1988; Briellmann
et al., 1985, Hering, 1988). Although some growth and
aggregation would be taking place during these additions
of oxalate , these studies were concerned mainly with
nucleation and were only pursued until the crystals
reached the chosen detection limit.
Concentration by Evaporation (Fig. 11 curve c)
Rapid evaporation of urine at 37C to a fixed
osmotic pressure (l.2osm/l) has been used to induce
crystallisation (Hallson & Rose, 1978) with the sample
being examined microscopically or chemically after
standing at 37C for one hour after concentration. When
calcium oxalate crystals were produced they were
mainly the dihydrate form often seen in urine. This
method has been used to compare fresh urine from stone
formers and control subjects (Hallson & Rose, 1978;
Azoury et al., 1987) and can be used to examine effects
of ultrafiltration or various additions (Hallson & Rose,
1979; Hallson et al., 1982 & 1983; Rose & Sulaiman,
1982 & 1984a & b; Grover et al., 1990c) . The
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Welshman & McGeown, 1972; Sallis & Lumley, 1979).
In these studies, crystallisation was allowed to proceed
for many hours and the net result will reflect nucleation,
aggregation and growth.
In gel systems, calcium and oxalate can be allowed
to diffuse towards each other through an agar gel and
crystallisation will occur at the boundary where they
meet. This can be quantified by changes in turbidity
and inhibitors or urine effects can be examined by
permitting them to diffuse into the crystallisation zone
(Roehrbom et al., 1986) . Another method is to include
oxalate and seed crystals in a gel and place the calcium
containing solution (which may be urine) above it.
Again diffusion will bring about supersaturation and the
crystallisation can be followed by the increase in
turbidity of the gel (Achilles et al., 1991). These
techniques can be easily applied to measure many
different samples . The relative diffusion rates of
different macromolecular components of the urine may
compromise these comparisons . On the other hand,
large crystals may form, which, as they are immobilised,
could be relevant to mechanisms that enable crystals
within the kidney to become sufficiently large to
become a clinical problem.

observed crystalluria may be in response to heterogeneous nucleators or homogeneous nucleation as a
result of the increased supersaturation. The change in
saturation for each urine will of course vary depending
on their initial saturation and osmotic pressure.
Although not amenable to rigorous analysis of
nucleation, crystal growth or aggregation, the method
has two distinct advantages. It can be used with fresh
whole urine and the concentration procedure may mimic
the water reabsorption that occurs in the upper part of
the urinary tract as the urine is formed.

Concentration by Reverse Osmosis (Fig. 1, curve d)
Another method which aims to reproduce intrarenal
development of supersaturation is reverse osmosis
(Azoury et al., 1986a, b & c). In these studies feed
solutions of calcium and oxalate, below supersaturation,
were forced at high pressure through hollow fibre
reverse osmosis membranes which are permeable only
to water . This is a continuous flow procedure and can
be so arranged as to have a transit time through the
apparatus comparable to transit times through the renal
tubules (about 3 minutes).
The water reabsorption
during this time was about 80% which generated
sufficient supersaturation to induce crystallisation, again
mainly of the dihydrate form. The crystals produced
were counted and sized and examined by scanning
electron microscopy and the composition of the output
stream analysed . The effects of some inhibitors were
examined in this system (Azoury et al., 1986a & b).
Apart from some effects on crystal numbers, changes in
the hydration habit of the crystals and extent of
aggregation were also noted . The main advantage of
this technique is that it may provide a good model for
generation of supersaturated urine within the kidney,
however, it would not be easy to analyse nucleation,
growth and aggregation processes separately.

Constant Supersaturation Systems
Constant Composition Crystallisers (Fig. 1, curve 0
Crystallisation of calcium oxalate and stone
formation in the kidney takes place in an environment
with a relatively constant supersaturation. Tomson &
Nancollas ( 1978) developed a technique to reproduce
this in vitro, which Sheehan & Nancollas (1980) applied
to studies of calcium oxalate monohydrate crystal
growth . These experiments are normally set up as for a
seeded crystallisation study in a metastable solution,
monitored with a calcium specific ion electrode . Small
changes in the potential measured by the electrode
trigger motorized syringes to add equimolar solutions of
calcium chloride and potassium oxalate so that constant
calcium and oxalate ionic activities are maintained. The
growth rate is found from the rate of addition of the
calcium or oxalate solutions, adjusting for volume
changes.
The driving force for crystallisation , (the
supersaturation), is held constant in this system and
growth rates are usually linear for more than 30
minutes, with second order kinetics being obeyed
(according to equation 4, with [Mt=eql calculated from
the thermodynamic solubility product) . As has been
found in conventional seeded systems, the growth rate
was proportional to the seed crystal concentration

Supersaturation Increased by Diffusion (Fig. 11
curves e 1 and ei.>.
Although not very widely used, it is possible to
raise the supersaturation of a test system by allowing
calcium or oxalate, or both, to diffuse into it. When this
approach has been used, the crystal products have
usually been immobilised by forming on glass fibre or
in a gel.
In the glass fibre method a thread is
suspended in a vessel containing urine or buffer and
calcium and oxalate allowed to diffuse in via two filter
paper wicks.
The resulting crystallisation can be
quantified by weighing the wick, dissolving the crystal
products and measuring calcium or measuring the
calcium in solution (Sutor, 1969; Dent & Sutor, 1971;
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(Sheehan & Nancollas, 1980). Crystallisation of the
trihydrate form of calcium oxalate also followed second
order kinetics, with a greater rate constant than for the
monohydrate (Sheehan & Nancollas, 1984).
The
inhibitory effect of urine or defined inhibitors could be
quantified, as before, by Langmuir adsorption isotherms,
leading to the inhibitor concentration (or urinary
dilution) required to bring about 50% inhibition
(Sheehan & Nancollas, 1980). In a study comparing
bladder and kidney urines, and examining the effect of
various urinary derived macromolecular fractions, simple
percentage inhibitions were presented (Lanzalaco et al.,
1988).
The optimal dilution of urine for this method was
suggested to be 1% to 2% (Lanzalaco et al., 1982) but
changes to the electrode design, later permitted use of
whole urine (Nancollas & Gaur, 1984). A 50% dilution
of urine reduced the growth rate by 92% of the control
rate (Gaur & Nancollas, 1984).
In simple seeded metastable solutions nucleation
should not be occurring, but this group have been able
to use their system to see if various factors can promote
nucleation. In the absence of seed crystals they noted
the time before any detectable crystallisation began (the
induction time) (White & Nancollas, 1987; Campbell et
al., 1989). Aggregation is not considered in this
method, although, as has already been discussed, this
may have an indirect effect on growth rates.
This constant composition approach has a number
of advantages.
It is a better model for the renal
environment than the systems described above and can
be operated at lower supersaturations than would be
used in non seeded conventional crystallisation
experiments. The constant supersaturation maintains a
constant driving force for all calcium oxalate hydrates
crystallising. By contrast, as the different hydrates have
different solubilities, [Mt]-[Mt=eql will not be the same
for different hydrates
throughout
a decaying
supersaturation experiment. In some circumstances,
dilution of test components during the procedure might
be important and the increasing crystal concentration
may indirectly effect growth and aggregation.

be estimated from the particle size distribution. For the
theoretical analysis to be valid, the system must be well
mixed and the outflow must be representative of the
remaining suspension . This is known as mixed
suspension, mixed product removal (MSl'v1PR). The use
of an MSl'v1PR crystalliser to study calcium oxalate
crystallisation therefore offers the opportunity of
obtaining physico-chemically meaningful data in a
crystallizing system which is a better model of kinetics
of crystallisation in the urine as it flows through the
kidney.
A calcium oxalate MSl'v1PR crystalliser usually
consists of a well mixed chamber with two input feed
lines and an output line, adjusted to maintain a constant
volume. Calcium and oxalate are introduced separately
through the feed lines at equal flow rates and after about
8-10 chamber volumes have flowed through the system,
equilibrium is achieved with a stable supersaturation and
particle size distribution. The average time particles
remain in the crystalliser is the residence time ('t),
't = V/Q
(19)
where V is the volume of the chamber and Q is the total
flow rate into (or out of) the chamber. If the crystals all
grow at the same rate and aggregation is neglected then
it can be shown that
(-L/G-t)
n = B0-re
(20)
or
Ln(n) = Ln(Bo-r)-L/G't
(21)
where n is the total number of crystals larger than size
L , G is the growth rate and Bo is the nucleation rate
(Rodgers & Garside, 1981). With appropriate units, G
can be measured as µm/min and Bo as no./min/ml from
the slope and intercept of the graph of Ln(n) against L,
according to equation 21. Using the growth and
nucleation rates it is possible to calculate the suspension
density (~.
in mg/I) according to the following
equation,
3 4
-6
~ = rrpB0G -r x 10
(22)
where p is the crystal density (g/cm\
There have been various applications of the
MSl'v1PRmethod, often with components being tested in
artificial urine (Miller et al. , 1977; Randolph & Drach,
1981; Li et al., 1985; Kohri et al., 1988 & 1989;
Robertson & Scurr, 1986). It has also been used with
dilute urine and macromolecular urinary fractions
(Drach et al., 1980 & 1982; Springmann et al., 1986).
MSl'v1PR
crystallisers used in urolithiasis research
are usually much smaller than their chemical
engineering counterparts and typically have volumes of
200ml to 400ml. Bearing in mind that about ten times
this volume must pass through until a steady state is
obtained, it is clear that only dilute urine could be used

Mixed
Suspension,
Mixed
Product
Removal
Continuous Crystallisers (Fig. 11 curve g)
The kidney is a continuous flow system with fresh
supersaturated urine being continuously formed and
passed out through the renal pelvis some minutes later
(Finlayson & Reid, 1978). Finlayson ( 1972) showed
that this could be described as a series of continuous
crystallisers. If certain assumptions are upheld, then the
crystallisation kinetics of a continuous crystalliser can
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those at high risk of recurrent disease and to test
possible treatments a_imed at preventing recurrence.
When the investigative goals are limited to physicochemical evaluation of effectors, then seeded
crystallisation from a metastable simple salt solution
may be most appropriate, with the constant composition
approach having some advantages over supersaturation
decay methods.
If the study objectives are directed towards stone
forming mechanisms, diagnosis or treatment, then the
relevance of experiments using dilute urine will always
be questionable. Nevertheless, there are methods which
employ dilute urine, as well as some which use whole
urine, which appear to discriminate between stone
formers and non stone formers and may be of diagnostic
value, or help in investigation of possible treatments.
When the methods used are not good models of stone
formation within the kidney then any differences
between patient groups must be considered empirical
and to be without a strong theoretical and mechanistic
foundation.
A good in vitro model of stone formation can
therefore be seen as crucial for improving our
understanding of the significance of the various
mechanisms involved and to enable the multitude of
crysta llisation studies to be put into perspective . No one
method answers all the requirements of a good model,
is applicable to whole urine and allows quantifiable
analysis of nucleation , growth and aggregation. Until
such a system is devised, different methods with
different advantages and disadvantages will continue to
be used. It would be helpful if, in future developments,
apparently arbitrary differences were kept to a minimum
and if new approaches were compared alongside
existing methods.

in such a system (Springmann et el. (1986) used 5%).
Recently a much smaller crystalliser with a volume of
20ml has been developed (Nishio et al ., 1991) and used
in a study with artificial urine (Nishio et al., 1990).
This system, applied to nearly whole urine (92%), forms
the basis of the experimental section of this paper.
The main disadvantage with the MSMPR system
is associated with aggregation. If this is significant it
could invalidate one of the assumptions underlying the
theoretical analysis of the particle size distribution . In
practice, if the plot of Ln(n) against L ( as in equation
21) is linear over most of the size range, then the
calculated growth and nucleation rates are assumed to
be realistic.
Robertson & Scurr (1986) used the
deviation from linearity at the extreme values of L, to
estimate aggregation effects. Springmann et al. (1986)
added a Couette agglomerator to their system in order
to study aggregation. Another problem is the relatively
high feed concentrations of calcium and oxalate that
must be supplied to the crystalliser. On the other hand,
it allows measurement of growth and nucleation rates as
independent parameters and the crystallisation takes
place in an environment much closer to that of a kidney
than is found with other systems.
Concluding Comments on Review Section
Many different methods have been used to study
calcium oxalate crystallisation in vitro. Some give a
general indication of the crystallization potential while
others are more specifically aimed at measuring growth,
nucleation or aggregation.
In supersaturated,
crystallising solutions it is not possible to study any one
of these processes completely in isolation, although
aggregation alone can be studied in a seeded system at
equilibrium (Hess et al., 1989).
The variation in response to a particular treatment
that might arise in different methods can not easily be
predicted from consideration of the technical details.
Unless more than one method is included in an
investigation then it is always likely to be difficult to
see the result of one experiment in perspective against
other studies. For instance, Grover et al. (1990c) using
two methods concluded that the different results with
Tamm-Horsfall
mucoprotein, as an effector of
crystallisation of calcium oxalate in urine, depended on
the method used.
The main objectives of in vitro calcium oxalate
crystallisation studies are to evaluate the physicochemical response of effectors of crystallisation; to
investigate mechanisms of stone formation and the role
of proposed effectors; as a diagnostic tool to identify

Experimental Techniques
Introduction

Mixed suspension, mixed product removal
(MSMPR) continuous crystallisation has some
advantages over other methods commonly applied to
studies of calcium oxalate crystallisation. Nucleation
rates can be measured as no./min/ml and growth rates as
µm/min, independently of each other, but at the same
time. The method offers a better representation of the
renal environment than other crystallisation techniques,
both because it reaches a steady state with a constant
supersaturation, and because it operates with continuous
flow; thus, individual crystals only remain in the
suspension for a relatively short time, not much different
from transit times through the kidney.
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and oxruate solution concentrations were estimated as
the difference between their initial concentration and the
suspension density, other electrolytes were measured
after
the
crystallisation
experiment
and
the
supersaturation calculated using EQUIL2 (Wemess et
al., 1985). Because of the uncertainty in our estimate of
M_,we refer to the supersaturation as an index, rather
than a ratio.
In a second series of experiments, two crystallisers
were run simultaneously with the same urine . Fresh
urine from control subjects was obtained and centrifuged
as before and divided into two portions. Heparin or
hyaluronic acid was added to one aliquot. Each portion
was used as a feed solution for one of the crystallisers.
Calcium chloride and sodium oxalate solutions were fed
to each chamber (adjusted to give initial concentration
of 12mM Calcium and 2.4mM oxalate).
In these
experiments the urinary calcium was taken into account
but endogenous oxalate was neglected in making up
these feed solutions. Each concentration examined was
tested on four different urine samples.
Oxalate, sulphate and phosphate were measured by
high perfonnance
ion chromatography
(HPIC)
(Robertson & Scurr, 1984); chloride by HPIC at a lower
dilution; calcium and magnesium by atomic absorption;
sodium and pota ssium by atomic emission; citrate by
coupled enzyme assay; ammonium by Berthelot's
method and osmotic pressure by freezing point
depression . Hyaluronic acid and heparin were obtained
from the Sigma Chemical company . Molecular weights
of 20,000 and 30,000, respectively, were used to
calculate concentrations.
The statistical significance of results was assessed
by analysis of variance (ANOV A), with repeated
measures
when
appropriate .
Logarithmic
transfonnations were used for growth and nucleation
rates to give nonnally distributed data. Including other
factors, such as urinary ionic strength, in the statistical
treatment of results allows their influence to be taken in
account. Multiple linear regression was used to examine
which additional
factors were significant
and
independent and should be included . Tukeys critical
range test was used to identify significant effects
(p<0.05) in ANOV As with multiple groups.

Applications of the MSMPR approach have
previously been limited to artificial urine, with up to 5%
urine included (Springmann et al., 1986)). The main
reason for using dilute urine is the volume requirements.
Most MSMPR crystallisers would need between 2 and
4 litres of undiluted urine. Our small scale crystalliser
(Nishio et al., 1991) has a volume of 0.02 litres and
hence a total feed solution requirement of about 0.2
litres.
This experimental
section describes
some
experiments to study nucleation and growth rates in
fresh, minimally diluted urine (by a factor of 1.09) or to
92% of its initial concentration).

Materials and Methods
Urine samples were obtained from healthy men
with no history of urolithiasis and from male recurrent
renal stone fonners . Specimens (collected in a prewanned Dewar flask) were adjusted to pH 6.0 with HCl
or NaOH and analysed for calcium and oxalate. They
were filtered (8µm cellulose nitrate prefilter (Sartorius
Ltd.), 0.45µm membrane filter ((Millipore Ltd.),
perfonned at 37C) or centrifuged {3,000g for 5 minutes
at 37C).
This urine (at 37C) was used as one of three feed
solutions to the continuous crystalliser, pumped at 92%
of the total flow rate . The other two feed solutions
were calcium chloride and sodium oxalate , each flowing
at 4% of the total flow. Knowing the urinary calcium
and oxalate concentrations, it was possible to adjust
these two solutions at the start of each experiment to
give concentrations in the crystallisation chamber (if no
precipitation occurred) of 12mM calcium and 2.4mM
oxalate. The experiments were started about 30 minutes
after the sample was passed and completed about l hour
later . The crystalliser chamber (see Nishio et al. (1991)
for details) had a volume of 20ml and was kept at 37C.
An average residence time ('t) of 6.7 minutes was used.
When equilibrium had been reached the particle
size distribution was measured (El zone 80XY, Particle
Data Inc.) . Crystal growth rates (G, µm/min) and
nucleation rates (Bo, no./min/ml) were calculated from
the slope and intercept of the data replotted as Ln no.
against size (see equation 21). The suspension density
(M_,mg/I) was calculated using ~uation 22 with the
crystal density taken to be 2.22g/cm . Occasionally the
calculated value of M_exceeded the amount of starting
material, probably because of errors in estimates of 't
and B0 . To overcome this problem, calculated values of
M_ were all scaled so that the maximum value
encountered would give a supersaturation of l. Calcium

Results
Comparison of control and stone formers urine.
Growth rates were found to be almost the same in
control and stone fonning groups and they did not differ
between centrifuged and filtered urines (Table 1).
Nucleation rates were higher in the control samples
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Table 1. MSMPR growth rates (µm/min) in 92% urine
from controls (Ctl) and stone formers (SF), centrifuged
(C) or filtered (F).

Table 3. MSMPR supersaturation indices in 92% urine
from controls (Ctl) and stone formers (SF), centrifuged
(C) or filtered (F).

controls

Geometric means (no. of samples)
centrifuged
filtered
C and F
0.65 (10)
0.64 (12)
0.64 (22)

controls

Means (no. of samples)
centrifuged
filtered
C and F
12.4 (10)
9.8 (12)
11.0 (22)

stone formers

0.65 (10)

0.68 (11)

stone formers

15.0 (10)

13.7 (11)

Ctl and SF

0.64 (20)

0.66 (23)

Ctl and SF

13.6 (20)

11.7 (23)

centifuged
versus
filtered
controls
versus
stone formers

0.66 (21)

Results from ANOV A
F (d.f.)
p
0.3 (1,39)
>0.1
0.1 (1,38) *

>0.1

0.2 (1,39)

>0.1

0.6 (1,38) *

>0.1

centifuged
versus
filtered
controls
versus
stone formers

*2nd ANOV A adjusts for the initial supersaturation of

34 (10)

53 (11)

Ctl and SF

48 (20)

83 (23)

centifuged
versus
filtered
controls
versus
stone formers

43 (21)

Results from ANOV A
F (d.f.)
p
3.2 (1,39)
0.08
4.9 (1,38) *

0.03

7.2 (1,39)

0 .01

10.7 (1,38)*

0.003

0.012

18.8 (1,39)

0.002

12.5 (1,38)

*

0.003

compared to the stone formers and higher in samples
which were filtered rather than centrifuged (Table 2).
The supersaturation within the crysta lliser was lower in
control samples than in urines from stone formers and
lower in filtered urine compared to centrifuged urine
(Table 3).
There were factors which our experimental design
did not control which might have varied between the
different groups and could, perhaps, explain the
observed differences in nucleation rates and
supersaturation. The urinary osmotic pressure (OP),
ionic strength (IS) and the supersaturation of the whole
urine samples (S 0) were considered as possible
confounding factors.
Their relationship to the
crystallisation kinetics was investigated. Crystal growth
rate was significantly related to s0 (p=0.001), OP
(p=0.040) and IS (p=0.041), but only s0 had a
significant and independent relationship with growth
rate. Nucleation rate was significantly related to s0
only (p=0.015).
The supersaturation index was
significantly related to IS (p=0 .025) and OP (p=0.025),
but only significantly and independently related to IS.
The significant and independent factor was included in
a second ANOV A, allowing its influence to be
discounted. This reinforced the conclusions of the first
ANOV A (Tables 1-3).

3

stone formers

6.9 (I ,38)*

2nd ANOV A adjusts for the ionic strength of urine
samples.

Table 2. MSMPR nucleation rates x 10· (no./min/ml)
in 92% urine from controls (Ctl) and stone formers
(SF), centrifuged (C) or filtered (F).

controls

Results from ANOV A
F (d.f.)
p
6.7 (1,39)
0.013

*

urine samples.

Geometric means (no. of samples)
centrifuged
filtered
C and F
68 (10)
127 (12)
95 (22)

14.5 (21)

*

2nd ANOV A adjusts for the initial supersaturation of
urine samples.
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Figure 2. The relationship between nucleation rate and growth rate in 92 % urine, shown as Ln nucleation rate
against I/growth rate . The four groups of samples shown are A, controls/ filtered ; B, controls/ centrifuged; C ,
stone former s/ filtered ; D, stone formers/ centrifuged. The intercept s are A, 7.40 ; B, 6.87; C , 6.77; D , 6.08; the
common slope is 2.72.
An inverse relationship between the growth rates
and log nucleation rates was noted. Plots of LnB 0
against 1/G were significantly correlated (for all
samples , the correlation coefficient r was 0.7). Analysis
of variance of the regression data also showed the
relationship was highly significant (p=0.00001) , with the
intercepts (p=0 .0006), but not the slopes (p>0 .05) of the
regression lines being influenced by the type of sample.
Figure 2 shows the regression lines for the four groups
of samples . Using Tukeys multiple range test, the
intercept of the control/ filtered samples was
significantly greater than the other three samples and the
intercept of the stone formers/ centrifuged urine was
significantly lower than the others (p<0 .05)

Effect of heparin and hyaluronic acid.
Heparin and hyaluronic acid were added at various
conc entrations to chamber two while chamber one acted
as a control in parallel crystalliser experiments. Both
additives brought about significant dose dependent
decreases in total crystal numbers , nucleation rate and
an increase in growth rate (figures 3 and 4). The
ANOV A revealed overall significant differences
(p<0 .003) between chamber I and 2, for all parameters
measured . There was no difference for the control
experiment (p>0 .05), all three concentrations of heparin
and the highest two of hyaluronic acid gave significant
differences (p<0.05) . At the concentrations tested,
hyaluronic acid was less effective than heparin which
increased growth rate and decreased crystal numbers by
nearly 100% (figure 4) .
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Discussion

The response of urines to this challenging load of
calcium and oxalate differed between controls and
recurrent stone formers and also depended to a lesser
extent on whether the urines had been pre-treated by
filtration or centrifugation. The mean growth rate did
not differ between groups but the mean nucleation rate
was higher in control samples compared to stone
formers urine . The mass of crystalline material is
proportional to the product of the cube of the growth
rate and the nucleation rate and this was higher, and
hence the supersaturation lower , in the control group.
This reproduces observations with whole urine in which
stone formers have often been reported to have higher
supersaturations than controls (Fleisch, 1978; Robertson
et al., 1976, 1981).
The thermodynamic driving force for each sample
tested would be very similar as they all had the same
starting concentrations of calcium and oxalate. Their
response can be viewed as a balance between the two

These experiments demonstrate that an MSMPR
continuous crystalliser system can be applied to nearly
whole urine (92%). Some preliminary treatment to
remove any crystals or cellular debris that could act as
sites for heterogeneous nucleation was considered
necessary and the effects of filtration and centrifugation
were studied.
In order to compare samples from
different patients we adjusted all samples to the same
starting concentrations of calcium and oxalate. The
concentrations which were used were necessarily
somewhat higher than physiological, in order to bring
about sufficient crystallisation.
In the absence of
precipitation very high supersaturation would prevail and
this provides the thermodynamic driving force for the
crystallisation.
Nevertheless, the steady state
supersaturation actually achieved within the crystalliser
was not much higher than is typical of whole urine.
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developing into a clinically significant stone when
growing in a higher supersaturation environment.
The difference between filtered and centrifuged
samples is consistent with the widely held belief that
macromolecular
urinary
factors
are important
determinants of crystallisation in vivo. These pretreatments of the urine are likely to have removed a
different proportion of high molecular weight factors
such as Tamm-Horsfall mucoprotein.
In the experiments with two crystallisers running
in parallel, we have demonstrated an extension of the
MSMPR method for examining the effect of potential
crystallisation effectors, in nearly whole urine. This
avoids the need for comparing results from different
urines, which may have widely different compositions.
In the particular experiments
shown, effective
concentrations of heparin and hyaluronic acid were
higher than commonly found in other systems. This
may be because our experiments already include the
majority of endogenous urinary factors and large doses
of crystallisation effectors may be needed to bring about

competing mechanisms of supersaturation relief,
nucleation and growth. This balance can be seen in the
relationship between LnB 0 and 1/G in figure 2. The
observation that the slopes of these lines are the same
but the intercepts are different helps to explain the
difference between the groups of samples. It suggests
that, for a given value of G, the different groups have
different values of LnB 0 and furthermore , as the log
differences in B0 are the same for all values of G, then
the proportional difference in B0 will also be the same.
Taking the nucleation rate of the control/ filtered
samples as 100%, then for all values of G, the
nucleation rates of the other groups will be about 59%
(control/ centrifuged), 53% (stone formers/ filtered) and
27% (stone formers/ centrifuged).
The effect of the higher nucleation rate in the
control groups is to bring about a lower steady state
supersaturation and this may be a crucial protective
factor distinguishing stone formers from controls. Any
crystals which become temporarily lodged within the
kidney will have a greater chance of growing and
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InhibitiOi, of calcium oxalate crystallization by urinary
macromolecules. Urol. Res. 19, 165-169.
10. Bijvoet OLM, Blomen LJMJ, Will EJ & Van
Der Linden, H (1981). Growth kinetics of calcium
oxalate monohydrate . Ill. Variations of solution
composition. J. Cryst. Growth 64, 316-325.
11. Blomen UMJ, Will EJ, Bijvoet OLM & Van
Der Linden (1983). Growth kinetics of calcium oxalate
monohydrate . II . The variation of seed concentration. J.
Cryst. Growth 64, 306-315.
12. Briellmann Th, Hering F, Seiler H &
Rutihauser G (1985). The oxalate-tolerance value: a
whole urine method to discriminate between calcium
oxalate stone formers and others. Urol. Res. 13, 291295.
13. Campbell AA , Ebrahimpour A, Perez L,
Smesko SA & Nancollas, GH (1989). The dual role of
polyelectrolytes and proteins as mineralization promoters
and inhibitors of calcium oxalate monohydrate. Calcif.
Tissue Int. 45, 122-128.
14. Curreri PA , Onada G & Finlayson B (1981).
A comparative appraisal of adsorption of citrate on
whewellite seed crystals. J . Cryst. Growth 53, 209-214.
15. Dent CE & Sutor DJ (1971). Presence or
absence of inhibitor of calcium-oxalate crystal growth in
urine of normals and of stone formers. Lancet 2, 775778.
16. Drach GW, Thorson S & Randolph A (1980).
Effects of urinary organic macromol ecu les on
crystallization of calcium oxalate: enhancement of
nucleation . J. Urol. 123, 519-523.
17. Drach GW, Kraljevich Z & Randolph AD
(1982). Effects of high molecular weight urinary
macromolecules on crystallization of calcium oxalate
di hydrate . J. Urol. 127, 805-810.
18. Edyvane K, Hibberd CM, Harnett RM,
Marshall VR, & Ryall RL (1987). Macromolecules
inhibits calcium oxalate crystal growth and aggregation
in whole human urine . Clin. Chim. Acta 167, 329-338.
19. Fellstrom B, Backman U, Danielson BG ,
Holmgren K, Ljunghall S & Wikstrom B (1982).
Inhibitory activity of human urine on calcium oxalate
crystal growth: effect of sodium urate and uric acid.
Clin. Sci. 62, 509 -514.
20. Finlayson B (1972).
The concept of a
continuous crystalliser. its theory and application to in
vivo and in vitro urinary tract models. Invest. Urol. 9,
258-263.
21. Finlayson B (1978). Physicochemical aspects
of urolithiasis. Kidney Int. 13, 344-360.
22. Finlayson B & Reid F (1978). The expectation
of free and fixed particles in urinary stone disease.

further change.
Both heparin and hyaluronic acid
seemed to cause a shift in the balance between
nucleation and growth in favour of growth, with a net
increase in supersaturation.
This method of studying urine in two crystallisers
simultaneously might be usefully applied to examine the
in vitro response of urine from a particular individual to
a proposed therapeutic regime. As any prophylactic
measures would have to be followed for many years it
would be extremely useful to establish in advance the
likely efficacy of the treatment.
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Discussion with Reviewers
Reviewer I: How would the authors justify the use of
such high initial concentrations of calcium and oxalate
in their MSMPR system?
Author: Because the system is unseeded, the initial
supersaturation must be above the metastable limit and
most MSMPR studies have operated at or abov e the
extreme range of physiologically appropriate calcium
and oxalate concentrations . The concentrations used in
these experiments were higher than others have worked
with because of the inhibitory effect of the high urine
concentration . In order to be able to calculate the
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growth and nucleation rates. sufficient crystals must be
generated over a wide particle size range and this could
only be achieved by employing high initial calcium and
oxalate concentrations.
The steady state solution
concentrations would, of course, be very much lower.

Reviewer I:
Would not the use of such high
concentrations produce too high a slurry density (a) for
counting crystal numbers accurately and (b) for the
amount of inhibitors and promoters in urine?
Author: The maximum particle concentration generated
in the crystallisers was less than {i(),000/ml. The orifice
tube of the particle sizer had an aperture of 150µm and
the probability of there being more than one particle at
a time in the critical volume (three times the aperture
volume) is <.025, which I feel is an acceptable
coincidence level. If urinary inhibitors and promoters
are bound to crystal surfaces, then their effective
concentration in this system could indeed be
significantly reduced. This may explain why responses
to heparin and hyaluronic acid was only found at higher
concentrations than other workers have observed using
different experimental techniques.

in the system. How does this apply to other - naturally
occurring - urinary inhibitors when tested under the
same conditions?
Author: The promotion of growth rate under these
circumstances may well be a response to the inhibition
of the nucleation rate, this being the only means of
supersaturation relief once the nucleation rate has
diminished. We have no data yet on naturally occurring
urinary inhibitors but their overall effect in this system
would be a combination of any direct effects on
nucleation and growth and their response to the
supersaturation pressure. Thus a factor which acts as an
inhibitor of crystal growth in a seeded method may
appear to promote crystal growth in an MSMPRsystem.
H.-G. Tiselius: A higher nucleation rate was recorded
in urine from control subjects. It is suggested that this
reflects a protection from forming large crystals and
could be a distinguishing factor between stone formers
and normal subjects. Can you speculate on how this
increased nucleation is achieved? Is this process in any
way modified by the urine composition?
Author: It is generally assumed that heterogeneous
nucleation dominates over homogeneous nucleation in
vivo (text reference 21) and this is probably true of our
system as well. Therefore, increased nucleation could
be achieved either by increasing the number or the
characteristics of nucleation catalysts. The difference
between filtered and centrifuged urine samples suggests
that variation in the concentration of nucleators could be
an important factor. The urinary composition might
modify heterogeneous nucleator activity by altering the
interaction between nucleating crystals and catalyst,
which will depend on physico-chemical and structural
factors. There was some evidence of an effect of
urinary composition in the significant correlation
(p=0.015) between nucleation rate and the urinary
supersaturation before the MSMPR experiment was
started.

Reviewer I: What range of M_ values does the
authors' system produce?
Author: The calculated suspension densities (M_)
ranged from 22 to 775 mg/I. The distribution of values
was highly skewed with few high values and the mode
was 183 mg/I.
Reviewer I: Did the authors find any evidence of
crystal agglomeration in their studies? If so, how did
they handle this mathematically?
Author: Significant agglomeration in the MSMPR
system would result in non linear particle size
distributions when plotted as Ln(n) against L. In
practice we found that good straight lines were always
obtained for particles up to 30µm in diameter. Beyond
this size, deviations were sometimes noted but these
were not very reproducible. Therefore, no attempt was
made to handle these mathematically. Scanning electron
microscope images of filtered crystal slurries showed
well formed calcium oxalate di- and tri- hydrate crystals,
with no evidence of extensive aggregation.

H.-G. Tiselius: Is there any explanation of the reduced
nucleation in urine with additives of heparin and
hyaluronic acid?
Author: The experimental data shown here do not give
any direct information on the mechanism of nucleation
inhibition but adsorption of these macromolecules to the
surface of heterogeneous nucleators with reduction in
the interaction between the catalytic surface and
nucleating calcium oxalate is a plausible explanation.

B. Hess: At the high concentrations selected, heparin
and - to a lesser extent - hyaluronic acid in the author's
MSMPR continuous crystallizer system seem to inhibit
nucleation rate and to promote crystal growth, which
might be taken as an attempt to reduce the high
supersaturation with respect to calcium oxalate present
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